Compare ADIG & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADIG | CMPS |
|---|---|---|
| Founded | N/A | 2020 |
| Country | | United Kingdom |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2026 | 2020 |
| Metric | ADIG | CMPS |
|---|---|---|
| Price | $21.02 | $14.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.38 |
| AVG Volume (30 Days) | 681.6K | ★ 2.4M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.03 | $4.88 |
| 52 Week High | $30.99 | $15.87 |
| Indicator | ADIG | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 58.76 |
| Support Level | $20.28 | $12.95 |
| Resistance Level | $22.82 | $15.87 |
| Average True Range (ATR) | 1.03 | 0.84 |
| MACD | 0.24 | 0.07 |
| Stochastic Oscillator | 59.43 | 72.85 |
ADI Global Distribution Inc is a specialty distributor of professionally installed low-voltage products, including security and audio-visual (AV) solutions, serving commercial and residential markets through an omnichannel go-to-market platform. It sells to professional installers, dealers, and integrators. The company's product portfolio includes products from third-party suppliers across low-voltage categories, as well as products and services offered under its own brands. Its customer base includes independent contractors, systems integrators, and low-voltage specialists serving business, institutional, and residential end users.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.